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Background: We sought to evaluate the effects of aortic annulus size on valve
hemodynamics and clinical outcomes in those patients included in the PARTNER
randomized controlled trial (RCT) cohort A and the PARTNER non-randomized
continued access (NRCA) cohort.
Methods: Patients included the RCT (n¼574) and NRCA (n¼1358) cohorts were
divided in tertiles according to aortic annulus diameter (small, medium, large aortic
annulus; SAA, MAA and LAA, respectively) as measured by transthoracic echocar-
diography. Moderate-to-severe prosthesis-patient mismatch (PPM) was deﬁned as an
effective aortic oriﬁce area of 0.85 cm2/m2.
Results: In the RCT cohort, patients in the SAA tertile who underwent TAVR had a
lower incidence of PPM (39% vs. 63%, P¼0.01), and only a trend toward a higher
incidence of moderate-to-severe paravalvular leak (PVL) compared to SAVR (5.7%
vs. 0%, P¼0.06). In the LAA tertile, there were no differences in the rate of PPM
between groups and a signiﬁcant increase in moderate-to-severe PVL was associated
with TAVR (9% vs. 0%, P¼0.01). In the NRCA cohort, there were no differences in
PPM between the SAA and LAA tertiles, but a higher rate of moderate-to-severe PVL
was observed in the LAA tertile (5.9% vs. 11.5%, P¼0.004). Patients in the LAA
tertile had a higher mortality rate at 1-year follow-up compared to the SAA and MAA
tertiles (24.8%, 18.3% and 18.7%, respectively, P¼0.02), and differences persisted in
multivariable analysis (P¼0.048 for LAA vs. MAA, P¼0.035 for LAA vs. SAA).
Conclusions: Aortic annulus sizehad amajor impact onvalvehemodynamics and clinical
outcomes following AVR. This study highlights the importance of considering aortic
annulus size in the evaluation of high-risk patients who are candidates for AVR, and
suggests that TAVR may be the preferred strategy for those with smaller aortic annulus.
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Background: Transcatheter aortic valve-in-valve (VinV) implantation inside failed
bioprostheses is increasingly being performed. Stentless surgical valves lack ﬂuoro-
scopic markers and may pose unique challenges. We aimed to evaluate clinical out-
comes following aortic VinV procedures in stentless bioprostheses, using a large
global registry.
Methods: Aortic VinV procedures included in the Global Valve-in-Valve Registry
were investigated (553 procedures: 441 in stented bioprostheses, 112 stentless).
Results: Patients with failed stentless bioprostheses were younger and had similar
STS score in comparison with those with stented (73.4  13.9 vs. 78.6  8, p< 0.001;
10.7  8.3 vs. 12.1  10.6, p¼0.20, respectively). Stentless bioprostheses had a
longer median time to failure and failed more commonly with predominant regurgi-
tation (11 vs. 9 years, p¼0.02 and 58.9% vs. 21.8% in stented, p< 0.001), were larger
(23.8  2.1 vs. 23.0  2.1 in stented, p¼0.002) and had lower degree of stenosis in
comparison with stented: valve area 1.28  0.62cm2 vs. 0.88  0.43cm2, mean
gradient 48  28.6 mmHg vs. 64.7  26.8mmHg, respectively; p< 0.001 for both).
Stentless bioprostheses were more commonly treated by a CoreValve (65.1% vs.
34.7% SAPIEN, p< 0.001) and TEE was utilized more during these procedures
(75.2% vs. 62.6% in stented, p¼0.01). Device malposition was more common in
stentless and Mosaic stented valves (16.1%, 14.0% vs. 9.0% in non-Mosaic stented
valves, p¼0.03). Coronary occlusion was more common in stentless bioprostheses
(5.4% vs. 1.4% in stented, respectively, p¼0.01). Post procedural mean aortic valve
gradient was lower post stentless VinV procedures (11.7  7.2mmHg vs. 16.9 
9.1mmHg in stented, p< 0.001). Thirty-day and 1-year mortality rates were similar,
when comparing stented and stentless procedures: 8.9% vs.6.6% (p¼0.39), 17.9% vs.
16.6% (p¼0.68), respectively.
Conclusions: Aortic VinV implantation inside stentless bioprosthesis is challenging
and associated with more device malposition and coronary occlusion events. Never-
theless, VinV procedures performed in stentless bioprostheses resulted better valve
hemodynamics than in stented surgical valves and patient survival was similar.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/VaTCT-699
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Background: It is important to elucidate factors that are associated with a poor
outcome after transcatheter aortic valve replacement (TAVR) to improve patient se-
lection. Tricuspid regurgitation (TR) and right ventricular dysfunction (RVD)
adversely affect outcomes in patients with heart failure or mitral valve disease, but
their impact on outcomes in patients with severe aortic stenosis (AS) treated with
TAVR has not been well characterized.
Methods: Patients enrolled and treated in the PARTNER II trial (inoperable cohort)
(n¼553) were included and stratiﬁed according to the presence and severity of TR and
RVD (qualitatively measured) on the baseline (pre-TAVR) echocardiogram as
determined by a core lab. Multivariable Cox PH models were used to evaluate the
association between TR and RVD and 1-year all-cause death.
Results: TR severity and RV function were measured in 507 and 488 patients,
respectively. Patients with none/trace (n¼167), mild (n¼205), moderate (n¼117), and
severe (n¼18) TR had 1-year all-cause death rates of 16.9%, 17.2%, 32.6%, and
61.1%, respectively (p< 0.001). Patients with normal RV function (n¼335) and mild
(n¼110) or moderate/severe RVD (n¼39) had 1 year all-cause death rates of 19.0%,
25.5%, and 38.5%, respectively (p< 0.001). Increasing severity of TR (p¼0.003) and
RVD (p¼0.01) were also associated with increased re-hospitalization rates at 1 year.
After adjusting for age, sex, BMI, STS score, prior infarct, prior CABG, frailty,
permanent pacemaker, atrial ﬁbrillation, left ventricular ejection fraction, aortic
transvalvular mean gradient, and mitral regurgitation, moderate/severe TR was asso-
ciated with increased 1-year mortality (adjusted HR 1.73, 95% CI 1.09-2.75, p¼0.01),
whereas RVD was not (p¼0.67).
Conclusions: In very high risk patients with severe symptomatic AS undergoing
TAVR, moderate or severe TR is independently associated with increased 1-year
mortality whereas RVD was only associated with mortality in univariable analysis.
This may have implications for treatment decisions, including assessment of antici-
pated beneﬁt from TAVR and whether concomitant surgical treatment of TR should
be considered in operable patients.
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Background: Data on degree of device oversizing associated with optimal clinical
outcomes after transcatheter aortic valve replacement (TAVR) is limited.
Methods: multicenter analyses of consecutive transfemoral TAVR procedures
using either SAPIEN XT or CoreValve was utilized. Oversizing zones were deﬁned
for SAPIEN XT (5-20% area oversizing or 2.5-9.5% perimeter oversizing) and
for CoreValve (20-35% area oversizing or 9.5-16.2% perimeter oversizing). “favor-
able-SAPIEN XT” (FXT) zone and “favorable-CoreValve” (FCV) zone included
annular sizes for which implantation of either a SAPIEN XT or a CoreValve,
respectively, allowed for presumed favorable oversizing.
Results: A total of 368 patients were included in the study: 178 patients in the FCV
zone (treated by either CoreValve, n¼90 or SAPIEN XT, n¼88) and 190 patients in
the FXT zone (treated by either SAPIEN XT, n¼78, or CoreValve, n¼112). In FCV
zone, those treated by SAPIEN XT had more annular rupture and conversion to
cardiac surgery in comparison with those treated by CoreValve (3.4% vs. 0, p¼0.04
and 4.5% vs. 0, p¼0.02, respectively). In FXT zone, those treated by CoreValve hadlvular disease - Aortic: TAVR B205
